Keryx Biopharmaceuticals (KERX) Said SUN-MICRO Trial Failed to Meet its Primary Efficacy Endpoint
Tweet Send to a Friend
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced top-line results from its SUN-MICRO Phase 3 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
